Managing freedom-to-operate (FTO) risks in drug discovery startups
Events
News
07/01/2026
In 2026, the landscape for drug discovery startups has never been more competitive or patent-intensive. Advances in biologics, AI-assisted drug design, and global development strategies have accelerated innovation while significantly increasing intellectual property (IP) complexity. For startups in the drug discovery space, innovation is only part of the equation.
Read more